ARPC1B

Across TCGA pan-cancer cohorts, ARPC1B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARPC1B data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARPC1B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARPC1B expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, GBM, and HNSC are the cancer types where ARPC1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.735	0.938	.001	20	view →
GBM	OS	Tertile	All	0.228	0.529	.001	18	view →
HNSC	DFS	Tertile	All	0.511	0.746	.018	9	view →
PDAC	OS	Tertile	All	0.908	0.802	.010	9	view →
LUAD	OS	Median	III,IV	0.435	0.777	.007	7	view →
LSCC	DFS	Tertile	II,III,IV	0.617	0.910	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARPC1B–CCRCC (OS)

Open the CCRCC breakdown →